Healthcare & Pharmaceuticals

Govt to control distribution of GSK/Vir COVID-19 antibody in U.S. - FDA

1 minute read

A GlaxoSmithKline plant is seen in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Oct 8 (Reuters) - The U.S. Food and Drug Administration said on Friday distribution of GlaxoSmithKline (GSK.L) and Vir Biotechnology's (VIR.O) antibody treatment for COVID-19 would be controlled by the government.

The drug was authorized by the FDA in May but no supply deal was signed at the time with the U.S. government, which is already distributing rival treatments by Regeneron Pharmaceuticals Inc (REGN.O) and Eli Lilly (LLY.N). read more

It was not clear whether a contract had been signed between the government and GSK/Vir. The U.S. Department of Health and Human Services did not immediately respond to Reuters' request for comment.

The drug, sotrovimab, belongs to a class of drugs called monoclonal antibodies, which mimic natural antibodies the body generates to fight off infection.

Register now for FREE unlimited access to Reuters.com
Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters